What does qarziba — gross carrying value mean?

Reflects the initial cost or acquisition value of an intangible asset or royalty stream before accounting for accumulated amortization or impairment. It provides insight into the total capital investment allocated to the specific product line or intellectual property.

Ligand Pharmaceuticals LGND Qarziba — Gross carrying value

Similar metrics at other companies

AMEGross Carrying Amount

$5.13B+9.4%

TRVGross Carrying Amount

$403M-1.7%

DUKGross Carrying Amount

$296M0.0%

PEPGross Carrying Amount

$3.14B+6.8%

GDGross Carrying Amount

$3.94B+1.0%

MDLZGross Carrying Amount

$3.46B+3.0%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's qarziba — gross carrying value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's qarziba — gross carrying value?: Ligand Pharmaceuticals (LGND) reported qarziba — gross carrying value of $103.72M in Q1 2026.
What does qarziba — gross carrying value mean?: Reflects the initial cost or acquisition value of an intangible asset or royalty stream before accounting for accumulated amortization or impairment. It provides insight into the total capital investment allocated to the specific product line or intellectual property.